LINDSEY LASSITER: Open Payments
NPI 1225325632 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,202 in 112 payments from 20 companies in 2025. Trend: 2023 $1,862 · 2024 $2,068 · 2025 $2,202
Food & beverage: $2,102Education: $100
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 23 | $443 |
| AstraZeneca Pharmaceuticals LP | 18 | $368 |
| Mallinckrodt Hospital Products Inc. | 14 | $360 |
| United Therapeutics Corporation | 9 | $175 |
| Regeneron Healthcare Solutions, Inc. | 6 | $148 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $121 |
| GENZYME CORPORATION | 5 | $91 |
| Insmed, Inc. | 4 | $78 |
| Liquidia Technologies, Inc. | 5 | $66 |
| Merck Sharp & Dohme LLC | 2 | $58 |
Products named: ACTHAR, DUPIXENT, TRELEGY ELLIPTA, NUCALA, TEZSPIRE, Tyvaso, BREZTRI, FASENRA.
Industry payments across MS — which companies pay providers there.
